Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Lannett Company, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine
Details : Biosimilar insulin glargine is the most significant opportunity in the company's current pipeline. Recent estimated U.S. sales of long acting insulin glargine (Glaricon) are approximately $10 billion annually, according to IQVIA, although manufacturer re...
Product Name : Glaricon
Product Type : Peptide
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Lannett Company, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Collaboration
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
Details : The biosimilar insulin aspart is currently in development and Lannett will help manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) approval to market the product.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
September 02, 2021
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Lannett Company, Inc.
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
